» Articles » PMID: 35133083

Ferroptosis in Cancer and Cancer Immunotherapy

Overview
Publisher Wiley
Specialty Oncology
Date 2022 Feb 8
PMID 35133083
Authors
Affiliations
Soon will be listed here.
Abstract

The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry. The broad spectrum of injury and tumor tolerance are the main reasons for radiotherapy and chemotherapy failure. The effective rate of tumor immunotherapy as a new treatment method is less than 30%. Ferroptosis can be seen in radiotherapy, chemotherapy, and tumor immunotherapy; therefore, ferroptosis activation may be a potential strategy to overcome the drug resistance mechanism of traditional cancer treatments. In this review, the characteristics and causes of cell death by lipid peroxidation in ferroptosis are briefly described. In addition, the three metabolic regulations of ferroptosis and its crosstalk with classical signaling pathways are summarized. Collectively, these findings suggest the vital role of ferroptosis in immunotherapy based on the interaction of ferroptosis with tumor immunotherapy, chemotherapy and radiotherapy, thus, indicating the remarkable potential of ferroptosis in cancer treatment.

Citing Articles

Medium-Chain Fatty Acids Selectively Sensitize Cancer Cells to Ferroptosis by Inducing CD36 and ACSL4.

Han K, Li J, Yin S, Hu H, Zhao C Nutrients. 2025; 17(5).

PMID: 40077664 PMC: 11901882. DOI: 10.3390/nu17050794.


The marine xanthophyll diatoxanthin as ferroptosis inducer in MDAMB231 breast cancer cells.

Sansone C, Pistelli L, Brunet C Sci Rep. 2025; 15(1):8146.

PMID: 40059233 PMC: 11891320. DOI: 10.1038/s41598-025-91519-6.


Quasi Fe MIL-53 nanozyme inducing ferroptosis and immunogenic cell death for cancer immunotherapy.

Yan Z, Bai Y, Zhang S, Kong L, Wang Y, Sun H Nat Commun. 2025; 16(1):2290.

PMID: 40055308 PMC: 11889140. DOI: 10.1038/s41467-025-57542-x.


AC129507.1 is a ferroptosis-related target identified by a novel mitochondria-related lncRNA signature that is involved in the tumor immune microenvironment in gastric cancer.

Yu S, Liang J, Liu L, Chen M, Chen C, Zhou D J Transl Med. 2025; 23(1):290.

PMID: 40050892 PMC: 11887229. DOI: 10.1186/s12967-025-06287-8.


Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy.

Liu D, Wang Y, Sun Q, Mei D, Wang X, Su Y Acta Pharm Sin B. 2025; 15(1):526-541.

PMID: 40041902 PMC: 11873607. DOI: 10.1016/j.apsb.2024.10.006.


References
1.
Gan W, Dai X, Dai X, Xie J, Yin S, Zhu J . LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020; 22(2):246-256. PMC: 7076906. DOI: 10.1038/s41556-020-0463-6. View

2.
Ye L, Chaudhary K, Zandkarimi F, Harken A, Kinslow C, Upadhyayula P . Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers. ACS Chem Biol. 2020; 15(2):469-484. PMC: 7180072. DOI: 10.1021/acschembio.9b00939. View

3.
Chang L, Chiang S, Chen S, Yu Y, Chou R, Chang W . Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett. 2017; 416:124-137. DOI: 10.1016/j.canlet.2017.12.025. View

4.
Alim I, Caulfield J, Chen Y, Swarup V, Geschwind D, Ivanova E . Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke. Cell. 2019; 177(5):1262-1279.e25. DOI: 10.1016/j.cell.2019.03.032. View

5.
Yao X, Yang B, Wang S, Dai Z, Zhang D, Zheng X . A novel multifunctional FePt/BP nanoplatform for synergistic photothermal/photodynamic/chemodynamic cancer therapies and photothermally-enhanced immunotherapy. J Mater Chem B. 2020; 8(35):8010-8021. DOI: 10.1039/d0tb00411a. View